Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAARTED2: Cabazitaxel + Abiraterone vs Abiraterone in CRPC
NCT03419234Phase 2Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Apr 2018
- Primary completion
- Jan 2024
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cabazitaxel ginsenoside liposome injection in castration-resistant prostate cancer (CRPC), sponsored by ECOG-ACRIN Cancer Research Group. Started Apr 2018; status: active, not recruiting.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03419234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03419234.